Open original FDA record ↗Recall record
- FDA identifier
- Z-2425-2024
- Company in FDA record
- Randox Laboratories Ltd.
- FDA classification date
- Jul 24, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Cystatin C Reagent marketed without a 510 (k)
Source facts
- Action
- Randox issued Medical Deice Correction Letter (REC748) to end-users on 6/7/24 via email. Letter states reason for recall, health risk and action to take: Randox are discontinuing distribution of Cystatin C Reagent, Catalogue Number CYS4004 to and within United States of America and Puerto Rico, until further notice. NB The product is still performing as expected and there are no safety concerns with the functionality of the devices. This notification is strictly regulatory, as the affected devices require a new FDA Licence Action to be taken: Transmission of Customer Notification: Send a copy of the notification to all affected customers and to those who need to be aware within the organisation. Complete and return the response form (12187-QA) to technical.services@randox.com within five working days. If you have any questions or concerns, please contact Randox Technical Services
- Initiated
- 2024-06-07
- Root cause
- No Marketing Application
- Distribution
- US Nationwide distribution in the states of AL, CA, GA, NY.
- Recall number
- Z-2425-2024
- Recall status
- Open, Classified
- CDRH record ID
- 208497
- FDA classified
- 2024-07-24
- Recall event number
- 94858